Ascenta, sanofi-aventis deal

sanofi-aventis received exclusive, worldwide rights to Ascenta's small molecule inhibitors of protein-protein interactions between p53 and mdm2 p53 binding protein homolog ( MDM2; HDM2). The deal in...